华大基因
(300676)
| 流通市值：193.67亿 | | | 总市值：194.73亿 |
| 流通股本：4.16亿 | | | 总股本：4.18亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,631,472,352.82 | 671,910,156.79 | 3,866,920,764.06 | 2,825,935,926.99 |
| 营业收入 | 1,631,472,352.82 | 671,910,156.79 | 3,866,920,764.06 | 2,825,935,926.99 |
| 二、营业总成本 | 1,552,863,244.58 | 708,704,349.71 | 4,258,391,381.38 | 2,820,539,450.5 |
| 营业成本 | 903,092,164.75 | 379,323,920.01 | 2,263,225,007.91 | 1,548,174,697.1 |
| 税金及附加 | 7,539,175.62 | 2,734,548.46 | 19,837,665.52 | 12,759,204.55 |
| 销售费用 | 336,523,086.25 | 162,730,574.57 | 1,009,984,667.46 | 663,331,251.16 |
| 管理费用 | 142,806,963.64 | 74,058,055.43 | 409,508,019.59 | 257,380,577.5 |
| 研发费用 | 227,606,241.47 | 117,331,387.43 | 606,174,523.75 | 398,014,771.1 |
| 财务费用 | -64,704,387.15 | -27,474,136.19 | -50,338,502.85 | -59,121,050.91 |
| 其中:利息费用 | 11,350,042.82 | 3,427,131.5 | 52,019,192.87 | 43,224,369.47 |
| 其中:利息收入 | 50,355,487.19 | 25,882,047.72 | 125,718,627.31 | 100,284,524.92 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 9,210,174.71 | 6,315,979.8 | -33,175,650.35 | -13,673,223.5 |
| 加:投资收益 | 18,665,756.39 | 3,416,203.88 | -43,626,260.23 | -21,845,253.45 |
| 资产处置收益 | -1,785,189.01 | -1,463,943.63 | -631,684.81 | 773,029.21 |
| 资产减值损失(新) | -7,094,614.66 | -3,031,168.63 | -242,207,529.14 | -6,428,202.01 |
| 信用减值损失(新) | -116,808,325.93 | -37,736,301.01 | -196,237,159.27 | -105,486,493.69 |
| 其他收益 | 8,460,197 | 3,119,666.43 | 32,581,142.88 | 21,564,378.19 |
| 四、营业利润 | -10,742,893.26 | -66,173,756.08 | -874,767,758.24 | -119,699,288.76 |
| 加:营业外收入 | 1,465,311.21 | 394,233.06 | 1,973,255.22 | 1,592,353.27 |
| 减:营业外支出 | 4,037,188.92 | 3,538,252.63 | 13,320,289.83 | 8,915,521.2 |
| 五、利润总额 | -13,314,770.97 | -69,317,775.65 | -886,114,792.85 | -127,022,456.69 |
| 减:所得税费用 | -17,459,517.16 | -14,022,369.71 | 25,986,290.31 | -2,842,029.91 |
| 六、净利润 | 4,144,746.19 | -55,295,405.94 | -912,101,083.16 | -124,180,426.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,144,746.19 | -55,295,405.94 | -912,101,083.16 | -124,180,426.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 5,778,221.12 | -52,695,120.08 | -902,690,862.44 | -124,166,136.95 |
| 少数股东损益 | -1,633,474.93 | -2,600,285.86 | -9,410,220.72 | -14,289.83 |
| 扣除非经常损益后的净利润 | -30,488,145.05 | -63,297,061.5 | -918,912,270.5 | -139,203,268.97 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | -0.13 | -2.19 | -0.3 |
| (二)稀释每股收益 | 0.01 | -0.13 | -2.19 | -0.3 |
| 八、其他综合收益 | -38,260,529.88 | -7,717,600.05 | 38,560,810.66 | -30,125,570.13 |
| 归属于母公司股东的其他综合收益 | -36,730,419.5 | -7,923,029 | 32,098,963.66 | -28,840,697.44 |
| 九、综合收益总额 | -34,115,783.69 | -63,013,005.99 | -873,540,272.5 | -154,305,996.91 |
| 归属于母公司股东的综合收益总额 | -30,952,198.38 | -60,618,149.08 | -870,591,898.78 | -153,006,834.39 |
| 归属于少数股东的综合收益总额 | -3,163,585.31 | -2,394,856.91 | -2,948,373.72 | -1,299,162.52 |
| 公告日期 | 2025-08-23 | 2025-04-26 | 2025-04-26 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |